• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eczematous reactions to psoriasis biologics treated with dupilumab: A case series.

作者信息

Koschitzky Merav, Tan Kathryn, Noliza Encarnacion Maria Rosa, Rivera-Oyola Ryan, Khattri Saakshi

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

出版信息

JAAD Case Rep. 2021 Mar 16;11:29-32. doi: 10.1016/j.jdcr.2021.03.006. eCollection 2021 May.

DOI:10.1016/j.jdcr.2021.03.006
PMID:33898680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8058610/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ea/8058610/7a3143883d72/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ea/8058610/951e6c162abe/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ea/8058610/7a3143883d72/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ea/8058610/951e6c162abe/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2ea/8058610/7a3143883d72/gr2.jpg

相似文献

1
Eczematous reactions to psoriasis biologics treated with dupilumab: A case series.使用度普利尤单抗治疗银屑病生物制剂引起的湿疹样反应：病例系列
JAAD Case Rep. 2021 Mar 16;11:29-32. doi: 10.1016/j.jdcr.2021.03.006. eCollection 2021 May.
2
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.度普利尤单抗与环孢素治疗成人中重度特应性皮炎：基于湿疹面积及严重程度指数的间接比较
Acta Derm Venereol. 2019 Sep 1;99(10):851-857. doi: 10.2340/00015555-3219.
3
Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.使用度普利尤单抗治疗的重度特应性皮炎患者的体重增加：一项队列研究。
BMC Dermatol. 2020 Sep 22;20(1):8. doi: 10.1186/s12895-020-00103-0.
4
Dupilumab: A review of its use in the treatment of atopic dermatitis.度普利尤单抗：治疗特应性皮炎的研究进展。
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. doi: 10.1016/j.jaad.2017.12.022.
5
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.度普利尤单抗联合外用皮质类固醇治疗中重度特应性皮炎的长期管理（LIBERTY AD CHRONOS）：一项为期 1 年、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.
6
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎成人患者。
N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.
7
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.度普利尤单抗在一大群难治性成人特应性皮炎患者中非常有效：来自 BioDay 登记处的首个临床和生物标志物结果。
Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31.
8
Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.采用敏感且特异的新型免疫分析法评估血清 IL-19 水平在银屑病和特应性皮炎中的作用及临床相关性。
Sci Rep. 2019 Mar 26;9(1):5211. doi: 10.1038/s41598-019-41609-z.
9
Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.度普利尤单抗治疗中重度特应性皮炎的经济学评估：一项成本效用分析。
J Drugs Dermatol. 2018 Jul 1;17(7):750-756.
10
Biologics-Induced Immunophenotypic Cross-Switching in Patients with Psoriasis and Atopic Dermatitis.生物制剂诱导的银屑病和特应性皮炎患者免疫表型交叉转换
Indian J Dermatol. 2023 Mar-Apr;68(2):186-191. doi: 10.4103/ijd.ijd_871_22.

引用本文的文献

1
Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort.靶向治疗甲银屑病：在一项为期24周的皮肤镜引导的真实世界队列研究中，白细胞介素-17A抑制剂相较于白细胞介素-23抑制剂表现出部位特异性优势。
Front Immunol. 2025 Apr 8;16:1573715. doi: 10.3389/fimmu.2025.1573715. eCollection 2025.
2
Genomic Profiling of the Overlap Phenotype between Psoriasis and Atopic Dermatitis.银屑病和特应性皮炎重叠表型的基因组分析。
J Invest Dermatol. 2024 Jan;144(1):43-52.e6. doi: 10.1016/j.jid.2023.06.194. Epub 2023 Jul 5.
3
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.

本文引用的文献

1
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.抗白细胞介素-17 治疗过程中出现的湿疹样发疹的临床和组织病理学特征：病例系列和文献复习。
Expert Opin Biol Ther. 2020 Jun;20(6):665-672. doi: 10.1080/14712598.2020.1727439. Epub 2020 Feb 17.
2
Eczematous reaction to ixekizumab successfully treated with dupilumab.使用度普利尤单抗成功治疗的对司库奇尤单抗的湿疹样反应。
Dermatol Ther. 2020 Mar;33(2):e13218. doi: 10.1111/dth.13218. Epub 2020 Jan 17.
3
Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.
度普利尤单抗治疗炎症性皮肤病：系统评价。
Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634.
度普利尤单抗治疗成人特应性皮炎期间银屑病样皮疹的发生：病例系列
Dermatol Ther. 2019 Nov;32(6):e13142. doi: 10.1111/dth.13142. Epub 2019 Nov 21.
4
Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.银屑病抗白细胞介素17治疗期间出现的湿疹样皮疹：一种新出现的情况。
Br J Dermatol. 2019 Sep;181(3):604-606. doi: 10.1111/bjd.17779. Epub 2019 May 14.
5
Atopic-like dermatitis after secukinumab injection: A case report.司库奇尤单抗注射后出现类特应性皮炎：一例报告。
Dermatol Ther. 2019 Jan;32(1):e12751. doi: 10.1111/dth.12751. Epub 2018 Nov 11.
6
Paradoxical eczematous reaction to ixekizumab.对司库奇尤单抗的反常湿疹样反应。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e40-e42. doi: 10.1111/jdv.15156. Epub 2018 Aug 13.
7
Eczematous drug eruption after ustekinumab treatment.使用乌司奴单抗治疗后出现的湿疹样药疹。
Arch Dermatol. 2012 Aug;148(8):959-60. doi: 10.1001/archdermatol.2012.586.
8
Interleukin-23: as a drug target for autoimmune inflammatory diseases.白细胞介素-23：作为自身免疫性炎症性疾病的药物靶点。
Immunology. 2012 Feb;135(2):112-24. doi: 10.1111/j.1365-2567.2011.03522.x.
9
Mutual antagonism of T cells causing psoriasis and atopic eczema.导致银屑病和特应性皮炎的T细胞相互拮抗。
N Engl J Med. 2011 Jul 21;365(3):231-8. doi: 10.1056/NEJMoa1104200.